JMJames A. McIntyre

James A. McIntyre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James A. McIntyre has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infant feeding knowledge, perceptions and practices among women with and without HIV in Johannesburg, South Africa: a survey in healthcare facilities

    by Coceka N. Mnyani, Carol L. Tait, Jean Armstrong, Duane Blaauw, Matthew F. Chersich, Eckhart J Buchmann, Remco P. H. Peters, James A McIntyre

    South Africa has a history of low breastfeeding rates among women with and without Human Immunodeficiency Virus (HIV). In this study, we assessed infant feeding knowledge, perceptions and practices among pregnant and postpartum women with and without HIV, in the context of changes in infant feeding and Prevention of Mother-to-Child Transmission of HIV (PMTCT) guidelines. This was a cross-sectional survey conducted from April 2014 to March 2015 in 10 healthcare facilities in Johannesburg, South Africa. A total of 190 pregnant and 180 postpartum women (74 and 67, respectively, were HIV positive) were interviewed using a semi-structured questionnaire. Multiple regression analyses assessed factors associated with an intention to exclusively breastfeed, and exclusive breastfeeding of infants less than six months of age. Women with HIV had better overall knowledge on safe infant feeding practices, both in general and in the context of HIV infection. There were however gaps in knowledge among women with and without HIV. Information from healthcare facilities was the main source of information for all groups of women in the study. A greater percentage of women without HIV 80.9% (93/115), reported an intention to exclusively breastfeed, compared to 64.9% (48/74) of women with HIV, p = 0.014. Not having HIV was positively associated with a reported intention to breastfeed, Adjusted Odds Ratio (AOR) 3.60, 95% CI 1.50, 8.62. Other factors associated with a reported intention to exclusively breastfeed were prior breastfeeding experience and higher knowledge scores on safe infant feeding practices in the context of HIV infection. Among postpartum women, higher scores on general knowledge of safe infant feeding practices were positively associated with reported exclusive breastfeeding, AOR 2.18, 95% CI 1.52, 3.12. Most women perceived that it was difficult to exclusively breastfeed and that cultural factors were a barrier to exclusive breastfeeding. While a greater proportion of women are electing to breastfeed, HIV infection and cultural factors remain an important influence on safe infant feeding practices. Healthcare workers are the main source of information, and highlight the need for accurate and consistent messaging for both women with and without HIV.


  • Open Access

    Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report

    by Mette S van Ramshorst, Magdeline Kekana, Helen E Struthers, James A McIntyre, Remco Ph Peters

    Background: Prepubertal gynecomastia is a rare condition and most frequently classified as idiopathic. In HIV-infected adults gynecomastia is a recognised but infrequent side-effect of antiretroviral treatment (ART) and mostly attributed to efavirenz use. Gynecomastia should be distinguished from pseudogynecomastia as part of the lipodystrophy syndrome caused by Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to avoid incorrect substitution of drugs. In the medical literature only five cases of prepubertal gynecomastia in children taking ART are described and underlying pathogenesis was unknown. The occurrence of adverse effects of ART may interfere with therapy adherence and long-term prognosis and for that reason requires attention. We report the first case of prepubertal gynecomastia in a young girl attributed to efavirenz use. Case presentation: A seven-year-old African girl presented with true gynecomastia four months after initiation on ART (abacavir, lamivudine, efavirenz). History, physical examination and laboratory tests excluded known causes of gynecomastia and efavirenz was considered as the most likely cause. Six weeks after withdrawal of efavirenz the breast enlargement had completely resolved. Conclusions: Efavirenz-induced gynecomastia may occur in children as well as in adults. With the increasing access to ART, the possibility of efavirenz-exposure and the potential occurrence of its associated side-effects may be high. In resource-poor settings, empirical change from efavirenz to nevirapine may be considered, providing no other known or alarming cause is identified, as efavirenz-induced gynecomastia can resolve quickly after withdrawal of the drug. Timely recognition of gynecomastia as a side-effect of efavirenz is important in order to intervene while the condition may still be reversible, to sustain adherence to ART and to maintain the sociopsychological health of the child.


  • Open Access

    HIV and Men Who Have Sex with Men in South Africa

    by James A. McIntyre, Helen Struthers


  • Can Devices for Adult Male Circumcision Help Bridge the Implementation Gap for HIV Prevention Services?

    by James A. MBChB McIntyre

    Medical male circumcision could prevent more than 5 million new HIV infections in men in Africa over 20 years and should be a central part of any combination prevention public health strategy. Surgical methods, with systems designed for high volume services, have been used in circumcision scale-up programs in several African countries, but remain limited by the need for high-level health workers, skilled in the surgical techniques, and appropriate facilities. New male circumcision devices such as the Shang Ring and the PrePex device have shown promise in initial trials and may provide innovative ways to improve access to medical male circumcision in the future. The rapid introduction of new and promising biomedical strategies for HIV prevention, including antiretrovirals for HIV prevention, will require early consideration of delivery systems and service design.


  • Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries

    by James McIntyre

    Purpose of review The purpose of the study was to review recent evidence on the use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income settings. Recent findings Access to antiretroviral prophylaxis strategies for HIV-infected pregnant women has increased globally, but two-thirds of women in need still do not receive even the simplest regimen for the prevention of mother-to-child transmission of HIV, and most pregnant women in need of antiretroviral treatment do not receive it. The use of combination antiretroviral treatment in pregnancy in low-resource settings is safe and effective, and increasing evidence supports starting ongoing antiretroviral treatment at a CD4 cell count below 350/μl in pregnant women. The use of appropriate short-course antiretroviral prophylactic regimens is effective for prevention of mother-to-child transmission of HIV in women with higher CD4 cell counts. New data on the use of antiretroviral prophylaxis to prevent transmission through breastfeeding demonstrate that both maternal antiretroviral treatment and extended infant prophylaxis are effective. Summary Antiretroviral use in pregnancy can benefit mothers in need of treatment and reduce the risk of mother-to-child transmission. Emerging evidence of the effectiveness of antiretroviral prophylaxis in preventing transmission through breastfeeding is encouraging and likely to influence practice in the future.


  • Open Access

    Monitoring HIV Antiretroviral Therapy in Resource‐Limited Settings: Time to Avoid Costly Outcomes

    by Frederick K. Sawe, James A. McIntyre

    There has been a dramatic and commendable rapid scale-up of human immunodeficiency virus (HIV) prevention and care services in resource-limited settings, including sub-Saharan Africa in the past 5 years; thousands of lives have been saved, and >3 million people are now receiving antiretroviral therapy (ART). Although much remains to be done to continue the scale-up of HIV prevention, care, and treatment, we must strive to hold onto gains we have achieved. More efficacious drugs, which are less toxic, are easier to take, and have greater genetic barriers to the emergence of resistance, as well as improved models on how to best deliver HIV services, are needed.


  • Clinical performance of an in-house real-time RT-PCR assay using a fluorogenic LUX™ primer for quantitation of human immunodeficiency virus type-1 (HIV-1)

    by Natela Rekhviashvili, Wendy Stevens, Edmore Marinda, René Gonin, Gwynneth Stevens, James McIntyre, Robin Wood


  • Open Access

    Circumcision for prevention against HIV: marked seasonal variation in demand and potential public sector readiness in Soweto, South Africa

    by Guy de Bruyn, Martin D Smith, Glenda E Gray, James A McIntyre, Russell Wesson, Gary Dos Passos, Neil A Martinson


  • Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV

    by James A McIntyre

    The use of nevirapine to prevent mother-to-child transmission of HIV has been controversial. Claims of high rates of toxicity have not been confirmed in clinical trials or extensive programme experience of use of the regimen. Whilst single-dose nevirapine can reduce transmission rates to approximately 10-15%, this can be halved by the addition of single-dose nevirapine to short-course regimens of zidovudine. The selection of resistant virus is reported in 20-50% of mothers and 50% of infants following one dose of nevirapine, although the impact of this on future treatment options is not fully understood. An increased risk of severe hepatotoxicity has been reported with long-term nevirapine-containing triple-therapy treatment regimens in women with CD4+ counts > 250 cells/mm3.


  • Strategies to prevent mother-to-child transmission of HIV

    by James McIntyre

    This review describes recent advances in the prevention of mother-to-child transmission, focusing on the use of antiretroviral treatment strategies in pregnancy, and discusses the emergence of viral resistance following the use of nevirapine to prevent mother-to-child transmission. Mother-to-child transmission has been dramatically reduced in developed countries by the use of antiretroviral treatment and avoidance of breastfeeding. Highly active antiretroviral therapy use in pregnancy is recommended for women who require ongoing treatment, and, where available, is also very effective in reducing mother-to-child transmission in women with higher CD4 counts. The addition of a maternal and infant nevirapine dose to antenatal zidovudine can reduce transmission to below 5%, approximately half the transmission rate that can be achieved by single-dose nevirapine alone. The emergence of resistant virus following nevirapine use is a concern, occurring in up to 60% of mothers and 50% of infants following a single dose. Addition of zidovudine and lamivudine for 4–7 days postpartum can reduce the risk of resistance to 10%. There is broad consensus on an approach to preventing mother-to-child transmission, which provides antiretroviral treatment in pregnancy and beyond to those women who need it, and an effective prophylactic regimen for those who do not yet need treatment, These regimens include highly active antiretroviral therapy, where available, a zidovudine-plus-nevirapine regimen in other settings, or nevirapine alone where this is all that is possible. More work is needed on the impact of nevirapine resistance and on reducing breast-milk transmission.